Detection of capecitabine (Xeloda®) on the skin surface after oral administration

Palmoplantar erythrodysesthesia (PPE), or hand-foot syndrome, is a cutaneous toxicity under various chemotherapeutics contributing to the most frequent side effects in patients treated with capecitabine (Xeloda®). The pathomechanism of PPE has been unclear. Here, the topical detection of capecitabin...

Full description

Saved in:
Bibliographic Details
Published in:Journal of biomedical optics 2016-04, Vol.21 (4), p.047002-047002
Main Authors: Huang, Mao-Dong, Fuss, Harald, Lademann, Jürgen, Florek, Stefan, Patzelt, Alexa, Meinke, Martina C, Jung, Sora
Format: Article
Language:English
Subjects:
Administration, Oral
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic - administration & dosage
Antimetabolites, Antineoplastic - pharmacokinetics
Antimetabolites, Antineoplastic - therapeutic use
Capecitabine - administration & dosage
Capecitabine - pharmacokinetics
Capecitabine - therapeutic use
Female
Fluorine - analysis
Humans
Male
Middle Aged
Neoplasms - drug therapy
Skin - chemistry
Spectrum Analysis
Sweat - chemistry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c460t-b43d2f601ae9846bd4efd13bd41fa7a804b307603144b209ab706bb1108528ec3
cites cdi_FETCH-LOGICAL-c460t-b43d2f601ae9846bd4efd13bd41fa7a804b307603144b209ab706bb1108528ec3
container_end_page 047002
container_issue 4
container_start_page 047002
container_title Journal of biomedical optics
container_volume 21
creator Huang, Mao-Dong
Fuss, Harald
Lademann, Jürgen
Florek, Stefan
Patzelt, Alexa
Meinke, Martina C
Jung, Sora
description Palmoplantar erythrodysesthesia (PPE), or hand-foot syndrome, is a cutaneous toxicity under various chemotherapeutics contributing to the most frequent side effects in patients treated with capecitabine (Xeloda®). The pathomechanism of PPE has been unclear. Here, the topical detection of capecitabine in the skin after oral application was shown in 10 patients receiving 2500  mg/m2/day capecitabine. Sweat samples were taken prior to and one week after oral administration of capecitabine. Using high-resolution continuum source absorption spectrometry, the changes in concentrations of fluorine, which is an ingredient of capecitabine, were quantified and statistically analyzed. Here, we show an increase in fluorine concentrations from 40±10  ppb (2±0.5  pM) before capecitabine administration to 27.7±11.8  ppm (14.6±6.5  nM) after application, p
doi_str_mv 10.1117/1.JBO.21.4.047002
format article
fullrecord <record><control><sourceid>proquest_spie_</sourceid><recordid>TN_cdi_proquest_miscellaneous_1785214892</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1785214892</sourcerecordid><originalsourceid>FETCH-LOGICAL-c460t-b43d2f601ae9846bd4efd13bd41fa7a804b307603144b209ab706bb1108528ec3</originalsourceid><addsrcrecordid>eNp9kM1OFjEUhhujkR-9ADamS1jM0NOWzswSQQRCgjGYuGvazmkszjcztp0FXJQXwZVZ-IAFGlen6XmeNzkvITvAagBo9qE-_3hZc6hlzWTDGH9FNuFAsYrzFl6XN2tFJZRqN8hWSteMsVZ16i3Z4E3RoROb5OsxZnQ5TCOdPHVmRheysWFEuvsdh6k3d7_3aNnmH0jTzzDStERvHFLjM0Y6RTNQ06_CGFKO5j7oHXnjzZDw_ePcJt9OPl0dnVYXl5_Pjg4vKicVy5WVoudeMTDYtVLZXqLvQZQJ3jSmZdIK1igmQErLWWdsw5S1UI464C06sU1217lznH4tmLJeheRwGMyI05I0NAUE2Xa8oLBGXZxSiuj1HMPKxBsNTN9XqUGXKjUHLfW6yuJ8eIxf7Ar7Z-OpuwLUayDNAfX1tMSxnPvfxKt_Cc_YbZhfOg9_hzEHN-CX45O_1nPvxR9WMZiG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1785214892</pqid></control><display><type>article</type><title>Detection of capecitabine (Xeloda®) on the skin surface after oral administration</title><source>Open Access: PubMed Central</source><source>SPIE Digital Library</source><creator>Huang, Mao-Dong ; Fuss, Harald ; Lademann, Jürgen ; Florek, Stefan ; Patzelt, Alexa ; Meinke, Martina C ; Jung, Sora</creator><creatorcontrib>Huang, Mao-Dong ; Fuss, Harald ; Lademann, Jürgen ; Florek, Stefan ; Patzelt, Alexa ; Meinke, Martina C ; Jung, Sora</creatorcontrib><description>Palmoplantar erythrodysesthesia (PPE), or hand-foot syndrome, is a cutaneous toxicity under various chemotherapeutics contributing to the most frequent side effects in patients treated with capecitabine (Xeloda®). The pathomechanism of PPE has been unclear. Here, the topical detection of capecitabine in the skin after oral application was shown in 10 patients receiving 2500  mg/m2/day capecitabine. Sweat samples were taken prior to and one week after oral administration of capecitabine. Using high-resolution continuum source absorption spectrometry, the changes in concentrations of fluorine, which is an ingredient of capecitabine, were quantified and statistically analyzed. Here, we show an increase in fluorine concentrations from 40±10  ppb (2±0.5  pM) before capecitabine administration to 27.7±11.8  ppm (14.6±6.5  nM) after application, p&lt;0.001. The results show the secretion of capecitabine on the skin surface after oral administration, indicating a local toxic effect as a possible pathomechanism of PPE.</description><identifier>ISSN: 1083-3668</identifier><identifier>EISSN: 1560-2281</identifier><identifier>DOI: 10.1117/1.JBO.21.4.047002</identifier><identifier>PMID: 27117193</identifier><language>eng</language><publisher>United States: Society of Photo-Optical Instrumentation Engineers</publisher><subject>Administration, Oral ; Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic - administration &amp; dosage ; Antimetabolites, Antineoplastic - pharmacokinetics ; Antimetabolites, Antineoplastic - therapeutic use ; Capecitabine - administration &amp; dosage ; Capecitabine - pharmacokinetics ; Capecitabine - therapeutic use ; Female ; Fluorine - analysis ; Humans ; Male ; Middle Aged ; Neoplasms - drug therapy ; Skin - chemistry ; Spectrum Analysis ; Sweat - chemistry</subject><ispartof>Journal of biomedical optics, 2016-04, Vol.21 (4), p.047002-047002</ispartof><rights>2016 Society of Photo-Optical Instrumentation Engineers (SPIE)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c460t-b43d2f601ae9846bd4efd13bd41fa7a804b307603144b209ab706bb1108528ec3</citedby><cites>FETCH-LOGICAL-c460t-b43d2f601ae9846bd4efd13bd41fa7a804b307603144b209ab706bb1108528ec3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.spiedigitallibrary.org/journalArticle/Download?urlId=10.1117/1.JBO.21.4.047002$$EPDF$$P50$$Gspie$$H</linktopdf><linktohtml>$$Uhttp://www.dx.doi.org/10.1117/1.JBO.21.4.047002$$EHTML$$P50$$Gspie$$H</linktohtml><link.rule.ids>314,780,784,24043,27924,27925,55379,55380</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27117193$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huang, Mao-Dong</creatorcontrib><creatorcontrib>Fuss, Harald</creatorcontrib><creatorcontrib>Lademann, Jürgen</creatorcontrib><creatorcontrib>Florek, Stefan</creatorcontrib><creatorcontrib>Patzelt, Alexa</creatorcontrib><creatorcontrib>Meinke, Martina C</creatorcontrib><creatorcontrib>Jung, Sora</creatorcontrib><title>Detection of capecitabine (Xeloda®) on the skin surface after oral administration</title><title>Journal of biomedical optics</title><addtitle>J. Biomed. Opt</addtitle><description>Palmoplantar erythrodysesthesia (PPE), or hand-foot syndrome, is a cutaneous toxicity under various chemotherapeutics contributing to the most frequent side effects in patients treated with capecitabine (Xeloda®). The pathomechanism of PPE has been unclear. Here, the topical detection of capecitabine in the skin after oral application was shown in 10 patients receiving 2500  mg/m2/day capecitabine. Sweat samples were taken prior to and one week after oral administration of capecitabine. Using high-resolution continuum source absorption spectrometry, the changes in concentrations of fluorine, which is an ingredient of capecitabine, were quantified and statistically analyzed. Here, we show an increase in fluorine concentrations from 40±10  ppb (2±0.5  pM) before capecitabine administration to 27.7±11.8  ppm (14.6±6.5  nM) after application, p&lt;0.001. The results show the secretion of capecitabine on the skin surface after oral administration, indicating a local toxic effect as a possible pathomechanism of PPE.</description><subject>Administration, Oral</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antimetabolites, Antineoplastic - administration &amp; dosage</subject><subject>Antimetabolites, Antineoplastic - pharmacokinetics</subject><subject>Antimetabolites, Antineoplastic - therapeutic use</subject><subject>Capecitabine - administration &amp; dosage</subject><subject>Capecitabine - pharmacokinetics</subject><subject>Capecitabine - therapeutic use</subject><subject>Female</subject><subject>Fluorine - analysis</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasms - drug therapy</subject><subject>Skin - chemistry</subject><subject>Spectrum Analysis</subject><subject>Sweat - chemistry</subject><issn>1083-3668</issn><issn>1560-2281</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp9kM1OFjEUhhujkR-9ADamS1jM0NOWzswSQQRCgjGYuGvazmkszjcztp0FXJQXwZVZ-IAFGlen6XmeNzkvITvAagBo9qE-_3hZc6hlzWTDGH9FNuFAsYrzFl6XN2tFJZRqN8hWSteMsVZ16i3Z4E3RoROb5OsxZnQ5TCOdPHVmRheysWFEuvsdh6k3d7_3aNnmH0jTzzDStERvHFLjM0Y6RTNQ06_CGFKO5j7oHXnjzZDw_ePcJt9OPl0dnVYXl5_Pjg4vKicVy5WVoudeMTDYtVLZXqLvQZQJ3jSmZdIK1igmQErLWWdsw5S1UI464C06sU1217lznH4tmLJeheRwGMyI05I0NAUE2Xa8oLBGXZxSiuj1HMPKxBsNTN9XqUGXKjUHLfW6yuJ8eIxf7Ar7Z-OpuwLUayDNAfX1tMSxnPvfxKt_Cc_YbZhfOg9_hzEHN-CX45O_1nPvxR9WMZiG</recordid><startdate>20160430</startdate><enddate>20160430</enddate><creator>Huang, Mao-Dong</creator><creator>Fuss, Harald</creator><creator>Lademann, Jürgen</creator><creator>Florek, Stefan</creator><creator>Patzelt, Alexa</creator><creator>Meinke, Martina C</creator><creator>Jung, Sora</creator><general>Society of Photo-Optical Instrumentation Engineers</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160430</creationdate><title>Detection of capecitabine (Xeloda®) on the skin surface after oral administration</title><author>Huang, Mao-Dong ; Fuss, Harald ; Lademann, Jürgen ; Florek, Stefan ; Patzelt, Alexa ; Meinke, Martina C ; Jung, Sora</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c460t-b43d2f601ae9846bd4efd13bd41fa7a804b307603144b209ab706bb1108528ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Administration, Oral</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antimetabolites, Antineoplastic - administration &amp; dosage</topic><topic>Antimetabolites, Antineoplastic - pharmacokinetics</topic><topic>Antimetabolites, Antineoplastic - therapeutic use</topic><topic>Capecitabine - administration &amp; dosage</topic><topic>Capecitabine - pharmacokinetics</topic><topic>Capecitabine - therapeutic use</topic><topic>Female</topic><topic>Fluorine - analysis</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasms - drug therapy</topic><topic>Skin - chemistry</topic><topic>Spectrum Analysis</topic><topic>Sweat - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, Mao-Dong</creatorcontrib><creatorcontrib>Fuss, Harald</creatorcontrib><creatorcontrib>Lademann, Jürgen</creatorcontrib><creatorcontrib>Florek, Stefan</creatorcontrib><creatorcontrib>Patzelt, Alexa</creatorcontrib><creatorcontrib>Meinke, Martina C</creatorcontrib><creatorcontrib>Jung, Sora</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of biomedical optics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Mao-Dong</au><au>Fuss, Harald</au><au>Lademann, Jürgen</au><au>Florek, Stefan</au><au>Patzelt, Alexa</au><au>Meinke, Martina C</au><au>Jung, Sora</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Detection of capecitabine (Xeloda®) on the skin surface after oral administration</atitle><jtitle>Journal of biomedical optics</jtitle><addtitle>J. Biomed. Opt</addtitle><date>2016-04-30</date><risdate>2016</risdate><volume>21</volume><issue>4</issue><spage>047002</spage><epage>047002</epage><pages>047002-047002</pages><issn>1083-3668</issn><eissn>1560-2281</eissn><abstract>Palmoplantar erythrodysesthesia (PPE), or hand-foot syndrome, is a cutaneous toxicity under various chemotherapeutics contributing to the most frequent side effects in patients treated with capecitabine (Xeloda®). The pathomechanism of PPE has been unclear. Here, the topical detection of capecitabine in the skin after oral application was shown in 10 patients receiving 2500  mg/m2/day capecitabine. Sweat samples were taken prior to and one week after oral administration of capecitabine. Using high-resolution continuum source absorption spectrometry, the changes in concentrations of fluorine, which is an ingredient of capecitabine, were quantified and statistically analyzed. Here, we show an increase in fluorine concentrations from 40±10  ppb (2±0.5  pM) before capecitabine administration to 27.7±11.8  ppm (14.6±6.5  nM) after application, p&lt;0.001. The results show the secretion of capecitabine on the skin surface after oral administration, indicating a local toxic effect as a possible pathomechanism of PPE.</abstract><cop>United States</cop><pub>Society of Photo-Optical Instrumentation Engineers</pub><pmid>27117193</pmid><doi>10.1117/1.JBO.21.4.047002</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1083-3668
ispartof Journal of biomedical optics, 2016-04, Vol.21 (4), p.047002-047002
issn 1083-3668
1560-2281
language eng
recordid cdi_proquest_miscellaneous_1785214892
source Open Access: PubMed Central; SPIE Digital Library
subjects Administration, Oral
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic - administration & dosage
Antimetabolites, Antineoplastic - pharmacokinetics
Antimetabolites, Antineoplastic - therapeutic use
Capecitabine - administration & dosage
Capecitabine - pharmacokinetics
Capecitabine - therapeutic use
Female
Fluorine - analysis
Humans
Male
Middle Aged
Neoplasms - drug therapy
Skin - chemistry
Spectrum Analysis
Sweat - chemistry
title Detection of capecitabine (Xeloda®) on the skin surface after oral administration
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T05%3A50%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_spie_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Detection%20of%20capecitabine%20(Xeloda%C2%AE)%20on%20the%20skin%20surface%20after%20oral%20administration&rft.jtitle=Journal%20of%20biomedical%20optics&rft.au=Huang,%20Mao-Dong&rft.date=2016-04-30&rft.volume=21&rft.issue=4&rft.spage=047002&rft.epage=047002&rft.pages=047002-047002&rft.issn=1083-3668&rft.eissn=1560-2281&rft_id=info:doi/10.1117/1.JBO.21.4.047002&rft_dat=%3Cproquest_spie_%3E1785214892%3C/proquest_spie_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c460t-b43d2f601ae9846bd4efd13bd41fa7a804b307603144b209ab706bb1108528ec3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1785214892&rft_id=info:pmid/27117193&rfr_iscdi=true